Reports Q1 revenue $294.9M, consensus $278.66M. “In Q1, LivaNova achieved double-digit revenue and operating income growth in both the Cardiopulmonary and Neuromodulation segments,” said CEO Vladimir Makatsaria. “I am grateful to our teams around the world for their exceptional work and dedication to serving our patients and customers. Looking ahead, our priorities continue to emphasize execution, innovation and talent development. We are confident that by delivering in each of these areas, we will improve patient outcomes and create shareholder value.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIVN:
- LivaNova jumps nearly 12% after saying trial likely to meet primary endpoint
- LivaNova reports positive predictive outcome for OSPREY trial for OSA
- LivaNova management to meet with Jefferies
- LivaNova Prices $300M Convertible Notes, Secures Capped Calls
- LivaNova PLC Announces $300M Convertible Notes Offering
